	Substitute for form 1449A/PTO				COMPLETE IF KNOWN
	INFORMATION	DIS	CLOSURE	Application Number	10/533,028
l ,	STATEMENT BY	7 A TD	DI ICANIT	Filing Date	April 26, 2005
	STATEMENT DE	ALE	FLICANI	First Named Inventor	George D. Hartman
				Group Art Unit	30-80-Assigned 1624
	(use as many sheets	s as n	ecessary)	Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	20942P

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Docum Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY			

			FOREIGN I	ATEN	r documents	
Examiner Initials*	Cite No.	Office	Foreign Patent Document Kind Name of Patentee or Applicant			Date of Publication of Cited Document MM-DD-YYYY
JAR.	1	PCT	WO 00/30651		Novartis	06/02/2000
Ø P	2	PCT	WO 00/61186		Weichselbaum, R.R.	10/19/2000
		ļ				
	ļ					
	<u> </u>					
	L.,	<u></u>				
Examin Signatu			Dierakle	JB	Date Considered	8 06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 669. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form 'IDS Form' (IDS Folder), Merck & Co., 100., -7/12/2005

9	ubstitute for form 1449B/PTO				COMPLETE IF KNOWN
1	NFORMATIO		CLOSURE	Application Number	10/533,028
	TO A STORAGE AND I	D 37 A 10	DI ICANIT	Filing Date	April 26, 2005
3	STATEMENT BY APPLICANT	First Named Inventor	George D. Hartman		
		Group Art Unit	To Be Assigned 1624		
	(use as many shi	eets as n	ecessary)	Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket Number	20942P

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.							
WR.	3	Amirkhosravi, A., et. al., "Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis", Platelets, 10, pp. 285-292 (1999)							
	4	Brockelsby, J., et al., "VEGF Via VEGF Receptor-1 (Flt-1) Mimics preeclamptic Plasma in Inhibiting Uterine Blood Vessel Relaxation in Pregnancy: Implications in the Pathogenesis of Preeclampsia", Laboratory Investigation, 79, pp. 1101-1111 (1999)							
	5	Carlson, B.A., et al., "Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-dependent Kinase (CDK) 2 and CDK2 in Human Breast Carcinoma Cells", Cancer Research, 56, pp. 2973-2978 (1996)							
	6	Deckers, M.M.L., et al., "Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation", Endocrinology, 141, pp. 1667-1674 (2000)							
	7	Detmar, M., "The role of VEGF and thrombospondins in skin angiogenesis", Journal of Dermatological Science, 24, Suppl. (1), pp. S78-S84 (2000)							
	8	Dickinson, A.J., et al., "Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas", British Journal of Urology, 74, pp. 762-766 (1994)							
	9	Ellis, L.M., et al., "Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation", Surgery, 120, (5), pp. 871-878 (1996)							
	10	Gasparini, G. and Harris, A.L., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool", Journal of Clinical Oncology, 13, pp. 765-782 (1995)							
	11	Gerber, et al., "VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation", Nature Medicine, Vol. 5, (6), pp. 623-628 (1999)							
	12	Giatromanolaki, A., et al., "The angiogenic pathway 'vascular endothelial growth factor/fik-I(KDR)-receptor' in rheumatoid arthritis and osteoarthritis", Journal of Pathology, 194, pp. 101-108 (2001)							
	13	Glab, N., et al., "Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions", FEBS Letters, 353, pp. 207-211 (1994)							
	14	Greenberg, D.A., "Angiogenesis and Stroke", Drug News Perspect, 11, pp. 265-270 (1998)							
	15	Gunningham, S.P., et al., "Vascular Endothelial Growth Factor-B and Vascular Endothelial Growth Factor-C Expression in Renal Cell Carcinomas: Regulation by the von Hippel-Lindau Gene and Hypoxia", Cancer Research, 61, pp. 3206-3211 (2001)							
	16	Hasegawa, T., et al., "Intracortical osteoblastic osteosarcoma with oncogenic rickets", Skeletal Radiology, 28, pp. 41-45 (1999)							
	17	Jain, R.K., "Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy", Nature Medicine, Vol. 7, (9), pp. 987-989 (2001)							

Examiner Signature	Deepakleys	Date Considered	4/8/06	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merch & Co., Inc., -7/12/2005)

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB408A (07-05), Information Disclosure Statement by Applicate
Patent and Tradeport Office: U.S DEPARTMENT OF COMMERCE

Su	bstitute for form 1449B/PTO				COMPLETE IF KNOWN
I	NFORMATION	DIS	CLOSURE	Application Number	10/533,028
C	TO A TOTAL ACCIONATE TO:	W A D	DI ICANE	Filing Date	April 26, 2005
3	TATEMENT B	IAP	PLICANI	First Named Inventor	George D. Hartman
				Group Art Unit	To Re Assigned 1624
	(use as many sheets as necessary)			Examiner Name	To Be Assigned
Sheet	3	of	3	Attorney Docket Number	20942P

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
WK.	18	Kelland, L.R., "Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status", Expert Opinion on Investigational Drugs, 9, pp. 2903-2911 (2000)
	19	Kitagawa, M., et al., "Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase", Oncogene, 8, pp. 2425-2432 (1993)
	20	Levis, M., et al., "A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations", Blood, Vol. 98 (3), pp. 885-887 (2001)
	21	Losiewicz, M.D., et al., "Potent Inhibition of CDC2 Kinase Activity By The Flavonoid L86-8275", Biochemical and Biophysical Research Communications, 201, pp. 589-595 (1994)
	22	Nakagawa, M., et al., "Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts", FEBS Letters, 473, pp. 161-164 (2000)
	23	Paul, R., et al., "Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke", Nature Medicine, 7, pp. 222-227 (2001)
	24	Rak, J., et al., "Mutant ras Oncogenes Upregulate VEGF/VPF Expression: Implications for Induction and Inhibition of Tumor Angiogenesis", Cancer Research, 55, pp. 4575-4580 (1995)
	25	Senderowicz, A.M., "Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials", Investigational New Drugs, 17, pp. 313-320 (1999)
	26	Smith, Stephen K., "Regulation of angiogenesis in the endometrium", Trends in Endocrinology & Metabolism, Vol. 12, (4), pp. 147-151 (2001)
	27	Toi, M., et al., " Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer", Japan. J. Cancer Res., 85, pp. 1045-1049 (1994)
	28	van der Flier et al., "Vascular Endothelial Growth Factor in Bacterial Meningitis: Detection in Cerebrospinal Fluid and Localization in Postmortem Brain", J. Infectious Diseases, 183, pp. 149-153 (2001)
\downarrow	29	Williams, J.K., et al., "Tumor Angiogenesis as a Prognostic Factor in Oral Cavity Tumors", American Journal of Surgery, 168, pp. 373-380 (1994)

		^ ·			
Examiner Signature	Dreinak (ley	Date Considered	4/8	06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merch & Co., Inc., -7/12/2005

	Аррлоче	tor use throug	h 7/31/2006.	OMB 0651-0031
SUBSTITUTE for PTO/SB/08/	A (07-05).	Information Di	sciosure Sume	ment by Amilianne
Patent and T	rademark (Office; U.S DE	PARTMENT	OF COMMERCE

<u> </u>					Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE		
s	ubstitute for form 1449A/PTO	UPP	LEMENTAL	COMPLETE IF KNOWN			
]	NFORMATION J	PAS	GLOSURE	Application Number	10/533,028		
	STATEMENT BY	AE	DI ICANT	Filing Date	April 26, 2005		
			7 2005	First Named Inventor	George D. Hartman		
	17		<i>\begin{align*}{c} \begin{align*} \b</i>	Group Art Unit	To Be Assigned 1624		
	(use as many sheets		EMPS TO	Examiner Name	To Be Assigned		
Sheet	1	of	1	Attorney Docket Number	20942P		

U.S. PATENT DOCUMENTS								
Examiner nitials*	Cite No.	U.S. Patent Docum Number	Ment Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
		781						

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.	Foreign Patent Document Office Number		K	Cind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY 06/13/2002		
1/2/R	1	PCT WQ 02/45652		<u> </u>	tnown)	Merck & Co., Inc			
							00/13/2002		
DOR	2	PCT	WO 00/62778			Bristol-Myers Squibb Co.	10/26/2000		
<u></u>		<u> </u>							
		L							
		<u> </u>							

Examiner Signature	Duerak (leng	Date Considered	4-8	06

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPET 509. Draw line through citation if are in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Form" (IDS Form" (IDS Form) (IDS

BEST AVAILABLE COPY